Spiro<2.3>hexan-1-carbonitril | 20778-44-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Spiro<2.3>hexan-1-carbonitril
• 英文别名: Spiro[2.3]hexane-2-carbonitrile；spiro[2.3]hexane-2-carbonitrile
• CAS: 20778-44-3
• 化学式: C₇H₉N
• 分子量: 107.155
• InChiKey: NBXGMDYYXSKNBT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  cyclobutane-1,1-diylbis(methylene) bis(4-methylbenzenesulfonate) 、 氰化钠 生成 Spiro<2.3>hexan-1-carbonitril
  参考文献：
  名称：

  Seyden-Penne,J.; Roux-Schmitt,M.-C., Bulletin de la Societe Chimique de France, 1968, p. 3810 - 3812

  摘要：

  DOI：

文献信息

• [EN] INDAZOLYL-SPIRO[2.3]HEXANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF<br/>[FR] DÉRIVÉS D'INDAZOLYL-SPIRO [2,3] HEXANE-CARBONITRILE COMME INHIBITEURS DE LRRK2, COMPOSITIONS PHARMACEUTIQUES, ET UTILISATIONS DE CEUX-CI
  申请人：MERCK SHARP & DOHME

  公开号：WO2019074810A1

  公开（公告）日：2019-04-18

  The present invention is directed to substituted certain reversed indazole compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1A, R1B, X, Y, RZ and R2 are as defined herein, which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

  本发明涉及Formula (I)的某些取代的反向吲唑化合物及其药学上可接受的盐，其中R1A、R1B、X、Y、RZ和R2如本文所定义，这些化合物是LRRK2激酶的强效抑制剂，并且在治疗或预防LRRK2激酶参与的疾病，如帕金森病和本文所述的其他疾病和疾病中有用。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗LRRK-2激酶参与的这类疾病中使用这些化合物和组合物。
• Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof
  申请人：Merck Sharp & Dohme Corp.

  公开号：US11174248B2

  公开（公告）日：2021-11-16

  The present invention is directed to substituted certain reversed indazole compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1A, R1B, X, Y, RZ and R2 are as defined herein, which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

  本发明涉及式(I)的取代的某些反式吲唑化合物：及其药学上可接受的盐，其中R1A、R1B、X、Y、RZ和R2如本文所定义，它们是LRRK2激酶的强效抑制剂，可用于治疗或预防LRRK2激酶参与的疾病，如帕金森病和本文所述的其它疾病和紊乱。本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在预防或治疗涉及LRRK-2激酶的此类疾病中的用途。
• INDAZOLYL-SPIRO[2.3]HEXANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3694331A1

  公开（公告）日：2020-08-19
• Seyden-Penne,J.; Roux-Schmitt,M.-C., Bulletin de la Societe Chimique de France, 1968, p. 3810 - 3812
  作者：Seyden-Penne,J.、Roux-Schmitt,M.-C.

  DOI：——

  日期：——